DeannaLee M Beauvais Selected Research

Syndecans

1/2022	Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.
10/2019	VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.
10/2004	The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells.
1/2004	Syndecans in tumor cell adhesion and signaling.
6/2003	Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

DeannaLee M Beauvais Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 01/2004
4	Breast Neoplasms (Breast Cancer) 01/2022 - 06/2003
4	Carcinoma (Carcinomatosis) 01/2022 - 06/2003
3	Carcinogenesis 01/2022 - 03/2009
2	Neoplasm Metastasis (Metastasis) 10/2019 - 11/2010
1	Squamous Cell Carcinoma of Head and Neck 01/2022
1	Leukemia 01/2022
1	Multiple Myeloma 01/2016

Drug/Important Bio-Agent (IBA)

5	SyndecansIBA 01/2022 - 06/2003
5	Syndecan-1 (Syndecan 1)IBA 10/2019 - 06/2003
5	IntegrinsIBA 10/2014 - 06/2003
3	Phosphotransferases (Kinase)IBA 01/2022 - 10/2014
3	Peptides (Polypeptides)IBA 10/2019 - 03/2009
2	tyrosine receptor (receptor, tyrosine)IBA 01/2022 - 10/2014
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	RON proteinIBA 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022
1	Syndecan-2IBA 01/2022
1	heparanaseIBA 10/2019
1	Integrin alpha4beta1 (VLA-4)IBA 10/2019
1	EnzymesIBA 10/2019
1	Cell-Penetrating PeptidesIBA 10/2014
1	Proteins (Proteins, Gene)FDA Link 03/2009
1	Integrin alphaVbeta3IBA 10/2004
1	VitronectinIBA 10/2004
1	Syndecan-4IBA 06/2003
1	AntibodiesIBA 06/2003

Therapy/Procedure

1	Therapeutics 01/2022